Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
10 12 2019
Historique:
received: 30 08 2019
revised: 11 09 2019
accepted: 16 09 2019
entrez: 7 12 2019
pubmed: 7 12 2019
medline: 22 5 2020
Statut: ppublish

Résumé

Moderate and moderately severe renal impairment are common in patients with heart failure and reduced ejection fraction, but whether beta-blockers are effective is unclear, leading to underuse of life-saving therapy. This study sought to investigate patient prognosis and the efficacy of beta-blockers according to renal function using estimated glomerular filtration rate (eGFR). Analysis of 16,740 individual patients with left ventricular ejection fraction <50% from 10 double-blind, placebo-controlled trials was performed. The authors report all-cause mortality on an intention-to-treat basis, adjusted for baseline covariates and stratified by heart rhythm. Median eGFR at baseline was 63 (interquartile range: 50 to 77) ml/min/1.73 m Patients with heart failure, left ventricular ejection fraction <50% and sinus rhythm should receive beta-blocker therapy even with moderate or moderately severe renal dysfunction.

Sections du résumé

BACKGROUND
Moderate and moderately severe renal impairment are common in patients with heart failure and reduced ejection fraction, but whether beta-blockers are effective is unclear, leading to underuse of life-saving therapy.
OBJECTIVES
This study sought to investigate patient prognosis and the efficacy of beta-blockers according to renal function using estimated glomerular filtration rate (eGFR).
METHODS
Analysis of 16,740 individual patients with left ventricular ejection fraction <50% from 10 double-blind, placebo-controlled trials was performed. The authors report all-cause mortality on an intention-to-treat basis, adjusted for baseline covariates and stratified by heart rhythm.
RESULTS
Median eGFR at baseline was 63 (interquartile range: 50 to 77) ml/min/1.73 m
CONCLUSIONS
Patients with heart failure, left ventricular ejection fraction <50% and sinus rhythm should receive beta-blocker therapy even with moderate or moderately severe renal dysfunction.

Identifiants

pubmed: 31806133
pii: S0735-1097(19)37932-X
doi: 10.1016/j.jacc.2019.09.059
pii:
doi:

Substances chimiques

Adrenergic beta-Antagonists 0

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2893-2904

Subventions

Organisme : Department of Health
ID : CDF-2015-08-074
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn
Type : ErratumIn
Type : CommentIn

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Dipak Kotecha (D)

Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom; Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Victoria, Australia. Electronic address: d.kotecha@bham.ac.uk.

Simrat K Gill (SK)

Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom.

Marcus D Flather (MD)

Norwich Medical School, Faculty of Medicine and Health Science, University of East Anglia, Norwich, United Kingdom.

Jane Holmes (J)

Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.

Milton Packer (M)

Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas.

Giuseppe Rosano (G)

Centre for Clinical and Basic Research, Department of Medical Sciences, IRCCS San Raffaele Pisana, Rome, Italy.

Michael Böhm (M)

Kardiologie, Angiologie und Internistische Intensivmedizin, Universitatsklinikum des Saarlandes, Homburg/Saar, Germany.

John J V McMurray (JJV)

Robertson Institute of Biostatistics and Clinical Trials Unit, University of Glasgow, Glasgow, United Kingdom.

John Wikstrand (J)

Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.

Stefan D Anker (SD)

Department of Cardiology, Charite Campus Virchow-Klinikum, Berlin, Germany.

Dirk J van Veldhuisen (DJ)

University of Groningen, Department of Cardiology, University Medical Centre Groningen, RB Groningen, the Netherlands.

Luis Manzano (L)

Internal Medicine Department, Hospital Universitario Ramón y Cajal, Universidad de Alcalá (IRYCIS), Plaza de San Diego, Madrid, Spain.

Thomas G von Lueder (TG)

Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Victoria, Australia; Department of Cardiology, Oslo University Hospital, Oslo, Norway.

Alan S Rigby (AS)

Hull York Medical School, Faculty of Health Sciences, University of Hull, Kingston-upon-Hull, United Kingdom.

Bert Andersson (B)

Department of Cardiology, Sahlgrenska University Hospital and Gothenburg University, Gothenburg, Sweden.

John Kjekshus (J)

Rikshospitalet University Hospital and Faculty of Medicine, University of Oslo, Oslo, Norway.

Hans Wedel (H)

Health Metrics, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Frank Ruschitzka (F)

Klinik fur Kardiologie, UniversitätsSpital Zürich, Zürich, Switzerland.

John G F Cleland (JGF)

Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.

Kevin Damman (K)

University of Groningen, Department of Cardiology, University Medical Centre Groningen, RB Groningen, the Netherlands.

Josep Redon (J)

INCLIVA Biomedical Research Institute, Valencia, Spain.

Andrew J S Coats (AJS)

Centre for Clinical and Basic Research, Department of Medical Sciences, IRCCS San Raffaele Pisana, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH